Cost‐Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma

BACKGROUND. Treatment options for patients with platinum‐refractory, recurrent, metastatic head and neck squamous cell carcinoma (r/m HNSCC) are limited and prognosis is poor. The recent CheckMate 141 clinical trial demonstrated that nivolumab, an anti‐programmed cell death protein 1 monoclonal anti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Zargar, Mahdi, McFarlane, Thomas, Chan, Kelvin K.W., Wong, William W.L.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2017
Témata:
Health Outcomes and Economics of Cancer Care
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813741/
https://ncbi.nlm.nih.gov/pubmed/29021380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0277
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky